Homepage
Author:
Actinogen Medical
Posted Date:
April 1, 2026
Actinogen commences open-label phase of XanaMIA Alzheimer’s trial and provides business update
Actinogen Medical
April 1, 2026
Actinogen receives positive Interim Analysis recommendation from its independent Data Monitoring Committee to continue the XanaMIA pivotal Alzheimer’s disease trial
Actinogen Medical
February 2, 2026
